- Home
- CHH vs PTGX Comparison
CHH vs PTGX Comparison
Compare CHH & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHH | PTGX |
|---|---|---|
| Founded | 1939 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.2B |
| IPO Year | 1997 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CHH | PTGX |
|---|---|---|
| Price | $104.98 | $103.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $114.30 | $108.23 |
| AVG Volume (30 Days) | ★ 620.6K | 576.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.42 | N/A |
| EPS | ★ 0.44 | 0.05 |
| Revenue | ★ $1,596,793,000.00 | N/A |
| Revenue This Year | $66.74 | $874.25 |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $234.05 | ★ N/A |
| Revenue Growth | ★ 0.75 | N/A |
| 52 Week Low | $84.04 | $41.60 |
| 52 Week High | $136.45 | $107.84 |
Technical Indicators
Market Signals| Indicator | CHH | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 54.40 |
| Support Level | $92.66 | $95.40 |
| Resistance Level | $110.35 | $107.42 |
| Average True Range (ATR) | 4.39 | 3.82 |
| MACD | -2.31 | -0.51 |
| Stochastic Oscillator | 30.49 | 56.65 |
Price Performance
Historical ComparisonAbout CHH Choice Hotels International Inc.
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2025.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.